| Translate This News In |
|---|
In a modest laboratory research, Johnson & Johnson said on Thursday (local time) that its single-shot COVID-19 vaccine showed promising evidence of protection against the Delta strain quickly spreading across the US and other nations.
According to the company’s research, the vaccine had substantial, long-lasting effectiveness against the Delta version of SARS-CoV-2 and other common SARS-CoV-2 viral variations. Furthermore, the data revealed that the immune response was durable for at least eight months, the longest period of time tested to far. BioRxiv, a non-profit preprint server for the biological sciences, received the two preprint study summaries today.
According to the findings, the single-dose vaccine elicited neutralising antibody activity against the Delta variant at a level much higher than that recently seen in South Africa for the Beta (B.1.351) variant. Johnson & Johnson’s vaccine was 85 percent effective against severe/critical disease and protected against hospitalisation and death in the ensemble trial. The vaccination was consistently efficacious in all regions investigated worldwide, including South Africa and Brazil, where fast growing Beta and Zeta strains were prevalent during the study period.
“Today’s newly disclosed trials confirm the Johnson & Johnson COVID-19 vaccine’s ability to help protect people’s health around the world,” stated Paul Stoffels, MD, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson. “Our vaccination, we believe, provides long-term protection against COVID-19 and neutralises the Delta version. This adds to the growing body of clinical evidence demonstrating our single-shot vaccine’s capacity to protect against a variety of dangerous variations “Stoffels was also a contributor.
Johnson & Johnson’s Mathai Mammen, MD, PhD, Global Head, Janssen Research & Development, said: “The single-shot Johnson & Johnson COVID-19 vaccine elicits a significant neutralising antibody response that does not diminish over time, according to current data for the eight months investigated so far. A continuous and particularly robust and permanent cellular immune response is also observed.”
“With each additional dataset, we add to our firm foundation of proof that our single-dose COVID-19 vaccine is vital in ending the pandemic,” Mammen stated.
The data revealed that the Johnson & Johnson single-shot COVID-19 vaccination elicited humoral and cellular immune responses that lasted at least eight months, the study’s most recent timepoint.
During the emergency pandemic time, the vaccination is now available in many regions and nations at no cost. On February 27, it was granted an emergency use authorization (EUA) in the United States, and on March 11, the European Commission granted it a Conditional Marketing Authorization (CMA).
